WASHINGTON, D.C. (March 5, 2002) - Mary Pendergast, executive vice president for government affairs at Elan Pharmaceuticals, will testify tomorrow on behalf of the Biotechnology Industry Organization (BIO) on the reauthorization of the Prescription Drug User Fee Act (PDUFA).
||House Committee on Energy and Commerce
Subcommittee on Health - hearing on the reauthorization of PDUFA
||Wednesday, March 6, 2002, 10 a.m.
||2322 Rayburn House Office Building
||Mary Pendergast, executive vice president for government affairs
Lester Crawford, DVM, PhD, deputy commissioner
Food and Drug Administration
Timothy Franson, MD, vice president, clinical research & regulatory affairs, U.S.
Eli Lilly Research Laboratories
Alastair Wood, MD, assistant vice chancellor for research
Vanderbilt University School of Medicine
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.
# # #